心臓マーカー検査市場の評価：製品タイプ・適応症・バイオマーカータイプ・検査タイプ・エンドユーザー・地域別の機会および予測 (2017-2031年)

世界の心臓マーカー検査の市場規模は、2023年の60億7,000万米ドルから、2024年から2031年の予測期間中は8.6%のCAGRで推移し、2031年には117億4,000万米ドルの規模に成長すると予測されています。

同市場は近年著しい成長を遂げており、今後も力強い拡大ペースを維持すると予想されます。うっ血性心不全や心臓発作などの心血管疾患の有病率の増加により、心臓マーカー検査に対するニーズが高まっています。

心臓マーカーには、心臓の健康に関連するバイオマーカーを特定することを目的とした広範な診断検査や機器が含まれ、心臓関連疾患の診断や治療に不可欠です。このため、医師や医療の専門家は、心臓の状態をモニターし、リスクを評価し、早期に特定するために、これらの検査により多くを依存しています。さらに、心臓マーカー検査の分野は、技術的な向上により急激な変化を遂げています。新しいアプローチと強化された検査プロトコルは、診断の精度と速度を向上させ、迅速で効率的な患者対応を可能にしています。

さらに、高感度の心臓バイオマーカーの進歩は、専門家が心臓の問題を早期に発見し、最終的に患者の転帰を改善するのに役立っています。例えば、Abbott Laboratoriesは2024年2月にARCHITECT Myxovirus Multiplex Assayを発表しました。この検査法は、A型およびB型インフルエンザウイルス、呼吸器合胞体ウイルス (RSV)、パラインフルエンザウイルスなど、多くの呼吸器ウイルスを同時に検出することができます。この検査は、医療関係者が呼吸器感染症と似たような症状を呈する心臓疾患を鑑別するのに役立ちます。

心血管疾患の増加：

心臓マーカー検査の世界市場が急速に拡大しているのは、そのほとんどが心血管疾患の発生頻度の増加によるものです。心臓発作、脳卒中、うっ血性心不全は心血管系疾患の一例であり、これらは依然として世界の死因および罹患率の上位を占めています。心臓マーカー検査は、増大する健康問題に対する大きな需要により、現代の医療に不可欠なものとなりつつあります。世界の人口が高齢化し、食生活の乱れ、座りっぱなしの習慣、ストレスレベルの上昇などのライフスタイルの曖昧さが拡大するにつれて、心血管疾患の発生率が上昇しています。特に、心臓マーカー検査の必要性が高まっているのは、高齢化によって心臓関連疾患への罹患が拡大しているためです。心臓の異常を早期に発見し治療することは、生活の質を大きく改善することができるため、非常に重要です。意識の高まりにより、人々はより積極的に心臓の健康を管理するようになり、早期診断とリスク評価のための心臓マーカー検査の必要性が高まっています。心臓マーカー検査技術は、医療システムや医療組織によって購入され、予防医療プログラムに組み込まれています。

当レポートでは、世界の心臓マーカー検査の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の心臓マーカー検査市場の展望

• 市場規模・予測
• 製品タイプ別
  • 試薬・キット
  • 機器
• 適応症別
  • 心筋梗塞
  • うっ血性心不全
  • 急性冠症候群
  • 動脈硬化症
  • 虚血
• バイオマーカータイプ別
  • トロポニンI・T
  • クレアチンキナーゼ-MB
  • 脳性ナトリウム利尿ペプチド
  • ミオグロビン
  • 高感度C反応性タンパク質
  • その他
• 検査タイプ別
  • ラボ検査
  • ポイントオブケア検査施設
• エンドユーザー別
  • 病院ラボ
  • CROラボ
  • 学術機関
  • ポイントオブケア検査施設
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の心臓マーカー検査市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング、2023年

• 製品タイプ別
• 適応症別
• バイオマーカータイプ別
• 検査タイプ別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長推進因子
• 成長阻害因子 (課題・制約)

第9章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の展望

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• bioMerieux, Inc.
• Becton, Dickinson and Company
• Diasorin S.p.A.
• Tosoh Europe N.V.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 3. Global Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 4. Global Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 5. Global Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 6. Global Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 7. Global Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 8. Global Cardiac Marker Testing Market Share (%), By Region, 2017-2031F
• Figure 9. North America Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 10. North America Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 11. North America Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 12. North America Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 13. North America Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 14. North America Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 15. North America Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 16. North America Cardiac Marker Testing Market Share (%), By Country, 2017-2031F
• Figure 17. United States Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 18. United States Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 19. United States Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 20. United States Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 21. United States Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 22. United States Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 23. United States Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 24. Canada Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 25. Canada Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 26. Canada Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 27. Canada Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 28. Canada Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 29. Canada Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 30. Canada Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 31. Mexico Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 32. Mexico Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 33. Mexico Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 34. Mexico Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 35. Mexico Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 36. Mexico Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 37. Mexico Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 38. Europe Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 39. Europe Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 40. Europe Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 41. Europe Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 42. Europe Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 43. Europe Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 44. Europe Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 45. Europe Cardiac Marker Testing Market Share (%), By Country, 2017-2031F
• Figure 46. Germany Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 47. Germany Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 48. Germany Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 49. Germany Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 50. Germany Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 51. Germany Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 52. Germany Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 53. France Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 54. France Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 55. France Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 56. France Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 57. France Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 58. France Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 59. France Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 60. Italy Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Italy Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 62. Italy Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 63. Italy Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 64. Italy Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 65. Italy Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 66. Italy Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 67. United Kingdom Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 68. United Kingdom Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 69. United Kingdom Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 70. United Kingdom Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 71. United Kingdom Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 72. United Kingdom Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 73. United Kingdom Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 74. Russia Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 75. Russia Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 76. Russia Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 77. Russia Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 78. Russia Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 79. Russia Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 80. Russia Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 81. Netherlands Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 82. Netherlands Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 83. Netherlands Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 84. Netherlands Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 85. Netherlands Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 86. Netherlands Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 87. Netherlands Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 88. Spain Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Spain Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 90. Spain Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 91. Spain Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 92. Spain Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 93. Spain Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 94. Spain Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 95. Turkey Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 96. Turkey Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 97. Turkey Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 98. Turkey Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 99. Turkey Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 100. Turkey Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 101. Turkey Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 102. Poland Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 103. Poland Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 104. Poland Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 105. Poland Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 106. Poland Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 107. Poland Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 108. Poland Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 109. South America Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 110. South America Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 111. South America Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 112. South America Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 113. South America Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 114. South America Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 115. South America Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 116. South America Cardiac Marker Testing Market Share (%), By Country, 2017-2031F
• Figure 117. Brazil Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 118. Brazil Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 119. Brazil Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 120. Brazil Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 121. Brazil Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 122. Brazil Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 123. Brazil Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 124. Argentina Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 125. Argentina Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 126. Argentina Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 127. Argentina Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 128. Argentina Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 129. Argentina Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 130. Argentina Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 131. Asia-Pacific Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 132. Asia-Pacific Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 133. Asia-Pacific Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 134. Asia-Pacific Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 135. Asia-Pacific Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 136. Asia-Pacific Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 137. Asia- Pacific Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 138. Asia-Pacific Cardiac Marker Testing Market Share (%), By Country, 2017-2031F
• Figure 139. India Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 140. India Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 141. India Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 142. India Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 143. India Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 144. India Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 145. India Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 146. China Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 147. China Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 148. China Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 149. China Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 150. China Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 151. China Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 152. China Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 153. Japan Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 154. Japan Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 155. Japan Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 156. Japan Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 157. Japan Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 158. Japan Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 159. Japan Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 160. Australia Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 161. Australia Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 162. Australia Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 163. Australia Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 164. Australia Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 165. Australia Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 166. Australia Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 167. Vietnam Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 168. Vietnam Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 169. Vietnam Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 170. Vietnam Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 171. Vietnam Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 172. Vietnam Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 173. Vietnam Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 174. South Korea Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 175. South Korea Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 176. South Korea Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 177. South Korea Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 178. South Korea Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 179. South Korea Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 180. South Korea Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 181. Indonesia Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 182. Indonesia Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 183. Indonesia Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 184. Indonesia Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 185. Indonesia Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 186. Indonesia Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 187. Indonesia Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 188. Philippines Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 189. Philippines Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 190. Philippines Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 191. Philippines Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 192. Philippines Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 193. Philippines Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 194. Philippines Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 195. Middle East & Africa Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 196. Middle East & Africa Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 197. Middle East & Africa Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 198. Middle East & Africa Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 199. Middle East & Africa Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 200. Middle East & Africa Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 201. Middle East & Africa Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 202. Middle East & Africa Cardiac Marker Testing Market Share (%), By Country, 2017-2031F
• Figure 203. Saudi Arabia Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 204. Saudi Arabia Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 205. Saudi Arabia Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 206. Saudi Arabia Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 207. Saudi Arabia Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 208. Saudi Arabia Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 209. Saudi Arabia Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 210. UAE Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 211. UAE Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 212. UAE Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 213. UAE Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 214. UAE Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 215. UAE Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 216. UAE Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 217. South Africa Cardiac Marker Testing Market, By Value, In USD Billion, 2017-2031F
• Figure 218. South Africa Cardiac Marker Testing Market, By Volume, In Million Units, 2017-2031F
• Figure 219. South Africa Cardiac Marker Testing Market Share (%), By Product Type, 2017-2031F
• Figure 220. South Africa Cardiac Marker Testing Market Share (%), By Indication, 2017-2031F
• Figure 221. South Africa Cardiac Marker Testing Market Share (%), By Biomarker Type, 2017-2031F
• Figure 222. South Africa Cardiac Marker Testing Market Share (%), By Type of Testing, 2017-2031F
• Figure 223. South Africa Cardiac Marker Testing Market Share (%), By End-user, 2017-2031F
• Figure 224. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 225. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 226. By Biomarker Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 227. By Type of Testing Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global cardiac marker testing market is projected to witness a CAGR of 8.6% during the forecast period 2024-2031F, growing from USD 6.07 billion in 2023 to USD 11.74 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. There is a significant need for cardiac marker testing due to the increased prevalence of cardiovascular conditions such as congestive heart failure and heart attacks.

Cardiac markers include a broad spectrum of diagnostic tests and instruments targeted at identifying particular biomarkers associated with cardiac health and are essential to the diagnosis and treatment of heart-related disorders. Due to this, physicians and healthcare professionals depend more on these tests to monitor their heart status, assess risk, and identify early. Furthermore, the field of cardiac marker testing has undergone a radical change due to technological improvements. Novel approaches and enhanced testing protocols augment the precision and velocity of diagnosis, permitting expeditious and efficient patient handling.

Furthermore, advancing highly sensitive cardiac biomarkers is helping professionals identify cardiac problems early, ultimately leading to better patient outcomes. For instance, Abbott Laboratories introduced the ARCHITECT Myxovirus Multiplex Assay in February 2024. The assay can simultaneously detect many respiratory viruses, such as influenza A and B, respiratory syncytial virus (RSV), and parainfluenza viruses. The test can help medical professionals differentiate between respiratory infections and heart problems, which can occasionally present with similar symptoms.

Rising Incidences of Cardiovascular Diseases

The rapid expansion of the global market for cardiac marker testing is mostly due to the increased frequency of cardiovascular disorders. Heart attacks, strokes, and congestive heart failure are examples of cardiovascular disorders, which remain the world's top causes of death and morbidity. Cardiac marker testing is becoming integral to modern healthcare due to the tremendous demand for growing health concerns. The incidence of cardiovascular diseases is rising as the world's population ages and lifestyle ambiguities such as poor diets, sedentary habits, and elevated stress levels proliferate. Notably, the need for cardiac marker testing has increased due to the aging population's increased susceptibility to heart-related conditions. Identifying and treating cardiac abnormalities as soon as possible is critical because early identification and treatment can greatly improve the quality of life. Due to increased awareness, people are more proactive in managing their heart health, increasing the need for cardiac marker testing for early diagnosis and risk assessment. Technologies for cardiac marker testing are being purchased by healthcare systems and organizations, who include them in their preventative healthcare programs.

According to a report by WHO, globally, cardiovascular diseases (CVDs) account for 17.9 million deaths annually, making them the leading cause of death. Heart and blood vessel illnesses together referred to as CVDs include rheumatic heart disease, coronary heart disease, and cerebrovascular disease. Heart attacks and strokes account for more than four out of every five deaths from CVD, and one-third of these deaths happen too soon among those under the age of 70.

Furthermore, the COVID-19 pandemic has brought attention to the importance of heart health. The virus has been associated with a higher risk of cardiovascular problems, which emphasizes the importance of cardiac marker testing. Global health systems are increasingly emphasizing detecting cardiac problems in COVID-19 patients, highlighting the importance of quick, precise, and trustworthy diagnostic testing.

Technological Advancements to Increase Global Cardiac Marker Testing Market

Technological developments are essential for driving the growth of the global cardiac marker testing market to unprecedented heights, stimulating creativity, and changing the face of cardiac diagnostics. The sensitivity, accuracy, and efficiency of cardiac marker testing have improved dramatically due to these developments, greatly improving the market outlook. Developing and implementing very sensitive cardiac biomarkers is a noteworthy progression in this domain. These biomarkers enable the early and accurate detection of heart disorders by identifying even the smallest amounts of cardiac-specific proteins in the blood. For instance, troponin is a highly sensitive marker for myocardial injury that makes it possible to detect cardiac problems early. These advancements are essential for spotting cardiac issues long before symptoms, allowing prompt intervention and better patient outcomes.

Furthermore, technological advancements have made point-of-care testing (POCT) for cardiac markers possible. POCT devices make on-site testing quick and easy, eliminating the need for laborious laboratory analysis. These portable gadgets are very helpful when prompt diagnosis is essential in emergency rooms and critical care settings. POCT has expedited treatment decisions and shortened turnaround times, which has improved patient care while making healthcare systems more cost-effective.

The fields of cardiac marker testing have benefited greatly from advances in genetic testing and molecular diagnosis. These methods allow identifying genetic alterations and indicators linked to cardiovascular disorders. Customized treatment plans can be created by determining a person's genetic susceptibility to cardiac problems. It allows for the customization of therapies to the specific genetic composition of each patient. The degree of customization lowers the dangers connected with needless medical treatments while simultaneously improving patient care. Alongside these developments, the specificity and multiplexing power of cardiac marker tests have been significantly improved. It implies that a single test can provide a more thorough profile of a patient's cardiac health for clinicians, negating the need for numerous independent analyses. Furthermore, incorporating machine learning and artificial intelligence into cardiac marker testing may improve diagnostic precision and offer prediction insights, resulting in more proactive and focused patient care.

PocDoc, a prominent provider of personal diagnostics and digital health platforms, announced the launch of the world's first smartphone-based cardiovascular exam in January 2022. The test will first be available to pharmacies, private healthcare providers, and NHS providers. The new test will cover all five market lipid panels, and the company projects by lowering the number of staff members needed, their system would save millions of dollars annually.

Increasing Demand for Troponin

The market for cardiac marker testing is experiencing significant growth due to the innovative trend of high-sensitivity cardiac biomarkers. These sophisticated biomarkers, particularly high-sensitivity troponin assays, have dramatically improved cardiac diagnostic tests' sensitivity, accuracy, and clinical usefulness, completely changing the field. The high-sensitivity cardiac biomarkers, which can identify minute amounts of cardiac-specific proteins in the blood, are one of the main factors influencing the development. High-sensitivity troponin assays are far more sensitive than their conventional counterparts when identifying myocardial injury or stress, which may have limited sensitivity. It implies that medical professionals can identify cardiac problems long before symptoms appear, enabling prompt and accurate treatment. When diagnosing an acute myocardial infarction (heart attack), the significance of high-sensitivity cardiac biomarkers is especially noticeable. These indicators allow for prompt and precise diagnosis of minute and clinically important changes in troponin levels.

Early identification is essential as it allows quicker medical intervention, which can improve patient outcomes and lessen the severity of heart muscle damage. High-sensitivity cardiac biomarkers are essential for prognostication and risk assessment. They aid physicians in assessing the probability of upcoming cardiovascular events by offering more accurate and detailed information regarding a patient's cardiac health. This makes it easier to customize treatment programs and take preventative measures for people who are at risk, leading to more effective and individualized patient care. In addition to increasing diagnostic accuracy, the increasing use of high-sensitivity cardiac biomarkers has allowed medical professionals to make decisions quickly and with greater knowledge. Consequently, these biomarkers are propelling improvements in patient management and care.

In September 2022, Agilus Diagnostics Ltd., one of the diagnostic laboratory chains in India, introduced "Heart Assure," a specialized high-sensitivity Troponin I (hsTnI) test that may forecast the risk of a cardiac event in the target group. By delivering a heart health risk score and estimating the likelihood of a future cardiac event, the hsTnI is a straightforward blood test that can detect even minute levels of Troponin I (picogram/ml) in the blood and accurately forecast a cardiac event or injury.

North America to Dominate Global Cardiac Marker Testing Market Share

In the forecasted period, North America is anticipated to lead the global market for cardiac marker analyzers. Sedentary lifestyles, inactivity, poor diets, and stress are the main causes of the increase in the prevalence of many cardiovascular conditions, including atrial fibrillation, coronary artery disease, and strokes. The rise of the market is mostly attributed to the United States, among other regional countries. For instance, according to the January 2022 update from Cedars-Sinai, the most common type of heart surgery is coronary artery bypass graft surgery (CABG), known as coronary artery bypass or bypass surgery, with over 300,000 successful bypass surgeries performed annually in the United States. Furthermore, according to the CDC's July 2022 report, 20.1 million adults in the United States aged 20 and older have coronary heart disease, making it the most prevalent type of heart disease. Furthermore, the source states that approximately 805,000 Americans experience a heart attack each year and that a heart attack occurs every 40 seconds. Therefore, the high prevalence of cardiovascular disorders drives the need for sophisticated diagnostic tools to enable more effective treatment, which in turn fuels the market for cardiac markers. It is anticipated that regional market expansion will be boosted by the increasing demand for cardiac marker analyzers.

Future Market Scenario (2024 - 2031F)

One of the main factors contributing to the anticipated growth of the cardiac marker testing market is the increasing prevalence of cardiovascular diseases. The rising geriatric population is a factor that will propel market growth in the future. Given that technology is advancing, we can expect innovative technology in the market as well. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, in July 2022, Siemens Healthcare Private Limited launched the Atellica CI 1900 Analyzer, a clinical chemistry and immunoassay testing instrument, as well as a reduced volume version of its commercially available Atellica clinical chemistry and immunoassay testing solution at the Annual Scientific Meeting and Clinical Lab Expo.

Key Players Landscape and Outlook

Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed cardiac marker testers, to help researchers to bring their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.

Siemens Healthcare Private Limited's Atellica CH SOAPS Assay, a cutting-edge test that finds creatine kinase-MB (CK-MB), a crucial cardiac marker, was approved by the FDA in February 2023. The Atellica CH immunoassay analyzer, which offers faster turnaround times and more efficient workflow, is specifically designed for this assay.

The BD Vacutainer Troponin I Ultra test is the first and only FDA-approved point-of-care troponin test for diagnosing acute myocardial infarction (AMI). Becton, Dickinson and Company announced 2023 that it had received FDA approval for the test to be used in point-of-care settings.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Cardiac Marker Testing Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Product Type
  • 4.2.1. Reagents and Kits
  • 4.2.2. Instruments
    • 4.2.2.1. Chemiluminescence
    • 4.2.2.2. Immunofluorescence
    • 4.2.2.3. ELISA
    • 4.2.2.4. Immunochromatography
• 4.3. By Indication
  • 4.3.1. Myocardial Infraction
  • 4.3.2. Congestive Heart Failure
  • 4.3.3. Acute Coronary Syndrome
  • 4.3.4. Atherosclerosis
  • 4.3.5. Ischemia
• 4.4. By Biomarker Type
  • 4.4.1. Troponin I and T
  • 4.4.2. Creatine Kinase-MB
  • 4.4.3. Brain Natriuretic Peptide
  • 4.4.4. Myoglobin
  • 4.4.5. High-Sensitivity C-Reactive Protein
  • 4.4.6. Others
• 4.5. By Type of Testing
  • 4.5.1. Laboratory Testing
  • 4.5.2. Point-of-Care-Testing Facilities
• 4.6. By End-user
  • 4.6.1. Hospital Laboratories
  • 4.6.2. Research Contract Laboratories
  • 4.6.3. Academic Institutes
  • 4.6.4. Point-of-Care-Testing Facilities
  • 4.6.5. Others
• 4.7. By Region
  • 4.7.1. North America
  • 4.7.2. Europe
  • 4.7.3. Asia-Pacific
  • 4.7.4. South America
  • 4.7.5. Middle East and Africa
• 4.8. By Company Market Share (%), 2023

5. Global Cardiac Marker Testing Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Product Type
    • 5.1.2.1. Reagents and Kits
    • 5.1.2.2. Instruments
      • 5.1.2.2.1. Chemiluminescence
      • 5.1.2.2.2. Immunofluorescence
      • 5.1.2.2.3. ELISA
      • 5.1.2.2.4. Immunochromatography
  • 5.1.3. By Indication
    • 5.1.3.1. Myocardial Infraction
    • 5.1.3.2. Congestive Heart Failure
    • 5.1.3.3. Acute Coronary Syndrome
    • 5.1.3.4. Atherosclerosis
    • 5.1.3.5. Ischemia
  • 5.1.4. By Biomarker Type
    • 5.1.4.1. Troponin I and T
    • 5.1.4.2. Creatine Kinase-MB
    • 5.1.4.3. Brain Natriuretic Peptide
    • 5.1.4.4. Myoglobin
    • 5.1.4.5. High-Sensitivity C-Reactive Protein
    • 5.1.4.6. Others
  • 5.1.5. By Type of Testing
    • 5.1.5.1. Laboratory Testing
    • 5.1.5.2. Point-of-Care-Testing Facilities
  • 5.1.6. By End-user
    • 5.1.6.1. Hospital Laboratories
    • 5.1.6.2. Research Contract Laboratories
    • 5.1.6.3. Academic Institutes
    • 5.1.6.4. Point-of-Care-Testing Facilities
    • 5.1.6.5. Others
  • 5.1.7. United States*
    • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. By Value
      • 5.1.7.1.2. By Volume
    • 5.1.7.2. By Product Type
      • 5.1.7.2.1. Reagents and Kits
      • 5.1.7.2.2. Instruments
        • 5.1.7.2.2.1. Chemiluminescence
        • 5.1.7.2.2.2. Immunofluorescence
        • 5.1.7.2.2.3. ELISA
        • 5.1.7.2.2.4. Immunochromatography
    • 5.1.7.3. By Indication
      • 5.1.7.3.1. Myocardial Infraction
      • 5.1.7.3.2. Congestive Heart Failure
      • 5.1.7.3.3. Acute Coronary Syndrome
      • 5.1.7.3.4. Atherosclerosis
      • 5.1.7.3.5. Ischemia
    • 5.1.7.4. By Biomarker Type
      • 5.1.7.4.1. Troponin I and T
      • 5.1.7.4.2. Creatine Kinase-MB
      • 5.1.7.4.3. Brain Natriuretic Peptide
      • 5.1.7.4.4. Myoglobin
      • 5.1.7.4.5. High-Sensitivity C-Reactive Protein
      • 5.1.7.4.6. Others
    • 5.1.7.5. By Type of Testing
      • 5.1.7.5.1. Laboratory Testing
      • 5.1.7.5.2. Point-of-Care-Testing Facilities
    • 5.1.7.6. By End-user
      • 5.1.7.6.1. Hospital Laboratories
      • 5.1.7.6.2. Research Contract Laboratories
      • 5.1.7.6.3. Academic Institutes
      • 5.1.7.6.4. Point-of-Care-Testing Facilities
      • 5.1.7.6.5. Others
  • 5.1.8. Canada
  • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East and Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Product Type
• 6.2. By Indication
• 6.3. By Biomarker Type
• 6.4. By Type of Testing
• 6.5. By End-user
• 6.6. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Thermo Fisher Scientific Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products and Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus and Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Danaher Corporation
• 13.3. F. Hoffmann-La Roche Ltd.
• 13.4. Siemens Healthcare Private Limited
• 13.5. Abbott Laboratories
• 13.6. Bio-Rad Laboratories, Inc.
• 13.7. bioMerieux, Inc.
• 13.8. Becton, Dickinson and Company
• 13.9. Diasorin S.p.A.
• 13.10. Tosoh Europe N.V.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer